Management of Parkinson's disease

Wireless Brain Sensor Market Size to Reach USD 804.3 Million in 2028 | Rising Need to Diagnose Sleeping Disorders and Increasing Incidence of Traumatic Brain Injuries are Some Key Factors Driving Industry Demand, says Emergen Research

Retrieved on: 
Monday, December 6, 2021

Increasing prevalence of brain disorders is expected to drive market revenue growth between 2021 and 2028.

Key Points: 
  • Increasing prevalence of brain disorders is expected to drive market revenue growth between 2021 and 2028.
  • Increasing need to diagnose sleeping disorders is expected to demand for associated solutions and drive revenue growth of the global wireless brain sensor market to a significant extent over the forecast period.
  • The global wireless brain sensor market is expected to expand at a CAGR of 9.5% from USD 391.7 Million in 2020 to USD 804.3 Million by 2028.
  • Emergen Research has segmented global wireless brain sensor on the basis of product, application, end-use, and region:

Wireless Brain Sensor Market Size to Reach USD 804.3 Million in 2028 | Rising Need to Diagnose Sleeping Disorders and Increasing Incidence of Traumatic Brain Injuries are Some Key Factors Driving Industry Demand, says Emergen Research

Retrieved on: 
Monday, December 6, 2021

Increasing prevalence of brain disorders is expected to drive market revenue growth between 2021 and 2028.

Key Points: 
  • Increasing prevalence of brain disorders is expected to drive market revenue growth between 2021 and 2028.
  • Increasing need to diagnose sleeping disorders is expected to demand for associated solutions and drive revenue growth of the global wireless brain sensor market to a significant extent over the forecast period.
  • The global wireless brain sensor market is expected to expand at a CAGR of 9.5% from USD 391.7 Million in 2020 to USD 804.3 Million by 2028.
  • Emergen Research has segmented global wireless brain sensor on the basis of product, application, end-use, and region:

Global Home Healthcare Markets to 2027: Custodial Care, Domiciliary Care, & Non-medical Care - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 9, 2021

Home care is the supportive care like custodial care, domiciliary care, or non-medical care which provided at home by registered nurses (RNs), occupation therapists, physical therapists, and licensed practical nurses.

Key Points: 
  • Home care is the supportive care like custodial care, domiciliary care, or non-medical care which provided at home by registered nurses (RNs), occupation therapists, physical therapists, and licensed practical nurses.
  • Home healthcare is classified into various types such as Hospice, and Social Care.
  • Furthermore, increase in government initiatives and technological advancement will have the positive impact on global home healthcare market growth.
  • Moreover, increase in geriatric population is expected to propel the global home healthcare market growth.

Eisai to Launch Parkinson's Disease Treatment Equfina in South Korea

Retrieved on: 
Monday, February 1, 2021

TOKYO, Feb 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai's subsidiary in South Korea, has launched the Parkinson's disease treatment Equfina (safinamide mesilate, "safinamide").

Key Points: 
  • TOKYO, Feb 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai's subsidiary in South Korea, has launched the Parkinson's disease treatment Equfina (safinamide mesilate, "safinamide").
  • The estimated number of patients with Parkinson's disease is approximately 150,000 in South Korea.
  • This disease is designated as a rare intractable disease in South Korea.
  • Together with providing Equfina as a new treatment option for Parkinson's disease to patients in South Korea, Eisai will make further contributions to address the diversified needs of Parkinson's disease patients and their families in Asia, and increase the benefits provided to them.

Galenagen Receives Patent for Remote Monitoring of Parkinson's Disease

Retrieved on: 
Wednesday, September 16, 2020

RYE BROOK, N.Y., Sept. 16, 2020 /PRNewswire/ --Galenagen, LLC, announced todaythat the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.

Key Points: 
  • RYE BROOK, N.Y., Sept. 16, 2020 /PRNewswire/ --Galenagen, LLC, announced todaythat the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.
  • 10,776,453 relating to remote monitoring of Parkinson's Disease.
  • Galenagen's patent is directed to methods of employing remote data gathering and monitoring for diagnosing, staging and treatment of Parkinson's Disease, movement and neurological disorders and chronic pain.
  • The technology will help facilitate early Parkinson's staging and ongoing monitoring of a patient's condition.

Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020

Retrieved on: 
Friday, September 11, 2020

These data are among several studies and analyses of ONGENTYS being presented in collaboration with BIAL at the MDS Virtual Congress 2020 on September 1216 ( www.mdscongress.org/Congress/Registration.htm ).

Key Points: 
  • These data are among several studies and analyses of ONGENTYS being presented in collaboration with BIAL at the MDS Virtual Congress 2020 on September 1216 ( www.mdscongress.org/Congress/Registration.htm ).
  • "The Phase III post-hoc data analyses demonstrated the benefit of adding once-daily ONGENTYS to levodopa/carbidopa in patients with Parkinson's disease who have motor fluctuations.
  • "These data analyses demonstrated the benefit of adding once-daily ONGENTYS to levodopa/carbidopa earlier in the treatment regimen of patients with Parkinson's disease.
  • Similarly, hospitalizations were significantly more frequent in patients with a longer history of motor fluctuations (15% [n=18] vs 6% [n=12], P

Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease

Retrieved on: 
Friday, September 11, 2020

In this study, NBIb-1817 showed sustained improvement in motor function after two years, with improved UPDRS Part III off medication scores of -12.0 points (baseline 34.4).

Key Points: 
  • In this study, NBIb-1817 showed sustained improvement in motor function after two years, with improved UPDRS Part III off medication scores of -12.0 points (baseline 34.4).
  • Requirements for Parkinson's disease medications were also reduced (daily levodopa-equivalent dose reduction, average of -439.5 mg/day; baseline 1500.9 mg/day).
  • Preliminary safety data from both studies suggest that NBIb-1817 was well-tolerated, with no study drug-related serious adverse events (SAEs) reported.
  • "Parkinson's disease patients' motor function would be expected to worsen over three years, making these results very encouraging.

Novel Treatment Using Patient's Own Cells Opens New Possibilities to Treat Parkinson's Disease

Retrieved on: 
Wednesday, May 13, 2020

The progressive loss of brain cells called dopaminergic neurons plays a major role in the disease's development.

Key Points: 
  • The progressive loss of brain cells called dopaminergic neurons plays a major role in the disease's development.
  • "Because the cells come from the patient, they are readily available and can be reprogrammed in such a way that they are not rejected on implantation.
  • The McLean-MGH team reprogrammed a 69-year-old patient's skin cells to embryo-like pluripotent stem cells (called induced pluripotent stem cells) and then differentiated them to take on the characteristics of dopaminergic neurons, which are lost in Parkinson's.
  • While there is optimism about the future of Parkinson's disease treatments because of their work, Schweitzer cautions against declaring victory against the disease.

Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS® (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes

Retrieved on: 
Monday, April 27, 2020

"The Parkinson's disease community is encouraged by the FDA approval of a new add-on treatment option to help patients further control symptoms, enabling them to better cope with this progressive disease."

Key Points: 
  • "The Parkinson's disease community is encouraged by the FDA approval of a new add-on treatment option to help patients further control symptoms, enabling them to better cope with this progressive disease."
  • The FDA approval of ONGENTYS is supported by data from 38 clinical studies, including two multinational Phase III clinical studies (BIPARK-1 and BIPARK-2), with more than 1,000 Parkinson's disease patients treated with ONGENTYS.
  • Reducing the patient's levodopa dosage or the dosage of another dopaminergic drug may reduce dyskinesia that occurs during treatment with ONGENTYS.
  • Re-evaluate the patient's current therapies for Parkinson's disease and consider stopping ONGENTYS if a patient develops such urges while taking ONGENTYS.

Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease to be Presented at AAT-AD/PD

Retrieved on: 
Tuesday, March 31, 2020

Prasinezumab, a monoclonal antibody under development for the potential treatment of Parkinson's disease, is the focus of a worldwide collaboration between Prothena and Roche.

Key Points: 
  • Prasinezumab, a monoclonal antibody under development for the potential treatment of Parkinson's disease, is the focus of a worldwide collaboration between Prothena and Roche.
  • Baseline data from the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson's disease, will be presented in the following virtual oral session.
  • Prior to initiating clinical trials, the efficacy of prasinezumab was evaluated in various cellular and animal models of alpha-synuclein-related disease.
  • For more information on the Phase 2 PASADENA clinical study of prasinezumab in patients with early Parkinson's disease, visit clinicaltrials.gov and search NCT #03100149 or visit www.pasadenastudy.com .